A University of Queensland (UQ) developed antiviral surface coating that protects against COVID-19 and other existing and emerging viral and bacterial transmissions is being tested on the International Space Station.
AIBN researchers want HIV patients to have the option of taking a long-acting antiretroviral dose once a week, instead of having to take a dose every day.
The gold standard test for oesophageal cancer involves a tube being stuck down your throat. PhD scholar Ramlah Khamis is working on a better method that could, in turn, help lift survival rates.
From environmental and energy technologies to biofuels, organoids, and new platforms for vaccines and therapeutics, here’s a wrap of the AIBN's biggest moments from the past 12 months – and some exciting developments we’re looking forward to in 2024.
Researcher Jacob Earnshaw has joined the growing list of AIBN PhD scholars to embark on a UQ Startup AdVenture. This is what he picked up during his time in Singapore's busting entrepreneurial scene.
AIBN researchers are using synthetic brain organoid models, grown in a laboratory from human stem cells, to find new ways to rejuvenate brains that have been prematurely aged by COVID-19.
Two exciting AIBN projects have scored new funding to help industry collaborators crack the lucrative computer chip industry and capitalise on opportunities in waste-to-catalyst conversion
In 2023, a cure for ALS remains elusive, and there are still no treatments to reverse its effects. But AIBN researchers are piecing together information that could get us there.
Four AIBN-led projects have been recognised in latest round of the $220 million Australian Research Council Discovery scheme, a program that recognises research with economic, commercial, environmental, social and/or cultural benefits.
A new parcel of funding from the Australian Research Council (ARC) will establish a cutting-edge national network for magnetic resonance spectroscopy – and the AIBN’s Centre for Advanced Imaging is set to play a central role.
mRNA vaccines and therapies will be produced for clinical trials in a dedicated laboratory to be built at the Australian Institute for Bioengineering and Nanotechnology.
There has been a huge increase in studies on extracellular vesicles, as these biological ‘text messages’ can be harnessed to develop therapeutic and diagnostic approaches for diseases, such as cancer.
As Dr Birgitta Ebert can attest, the wider push for sustainability is more than replicating fossil-fuel processes and it includes developing more sustainable manufacturing processes that harness the power of our natural world and reduce our carbon footprint.